Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Unleashing the potential of CD39-targeted cancer therapy: Breaking new ground and future prospects

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 178, P. 117285 - 117285

Published: Aug. 11, 2024

The review article titled CD39 Transforming Cancer Therapy by Modulating Tumor Microenvironment published in June 2024 Letters provides a comprehensive overview of CD39's multifaceted roles cancer, particularly its influence on immunoregulation, angiogenesis, and metabolic reprogramming within the tumor microenvironment (TME). This commentary builds that foundation incorporating recent advancements research, highlighting unresolved issues, proposing future research directions. We delve into therapeutic potential targeting CD39, addressing clinical translation challenges, exploring integration CD39-based strategies precision oncology.

Language: Английский